{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:35:35Z","timestamp":1785893735845,"version":"3.56.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":971,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The IPI4 national phase IV study was financed by the Department of Health, Oslo, Norway","award":["1"],"award-info":[{"award-number":["1"]}]},{"name":"Antibody analyses were supported by The Cancer Clinic, Oslo University Hospital through the Metaflammation Strategic Focus Area.","award":["2"],"award-info":[{"award-number":["2"]}]},{"name":"This article is part of the PhD thesis of Marta Nyakas that is supported by Bodil and Magnes Foundation.","award":["3"],"award-info":[{"award-number":["3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,24]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>New therapies, including the anti-cytotoxic T lymphocyte antigen (CTLA)-4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients with metastatic or unresectable malignant melanoma, receiving treatment with ipilimumab in a national Phase IV study (NCT0268196). Expression of a panel of 17 inflammatory-related markers reflecting different pathways including extracellular matrix remodeling and fibrosis, vascular inflammation and monocyte\/macrophage activation were measured at baseline and the second and\/or third course of treatment with ipilimumab. Six candidate proteins [endostatin, osteoprotegerin (OPG), C-reactive protein (CRP), pulmonary and activation-regulated chemokine (PARC), growth differentiation factor 15 (GDF15) and galectin-3 binding-protein (Gal3BP)] were persistently higher in non-survivors. In particular, high Gal3BP and endostatin levels were also independently associated with poor 2-year survival after adjusting for lactate dehydrogenase, M-stage and number of organs affected. A 1 standard deviation increase in endostatin gave 1\u00b774 times [95% confidence interval (CI) = 1\u00b710\u20132\u00b778, P = 0\u00b7019] and for Gal3BP 1\u00b752 times (95% CI = 1\u00b701\u20132\u00b729, P = 0\u00b7047) higher risk of death in the adjusted model. Endostatin and Gal3BP may represent prognostic biomarkers for patients on ipilimumab treatment in metastatic melanoma and should be further evaluated. Owing to the non-placebo design, we could only relate our findings to prognosis during ipilimumab treatment.<\/jats:p>","DOI":"10.1111\/cei.13283","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T16:57:17Z","timestamp":1551459437000},"page":"74-82","source":"Crossref","is-referenced-by-count":46,"title":["Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma"],"prefix":"10.1093","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-3440","authenticated-orcid":false,"given":"M","family":"Nyakas","sequence":"first","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Aamdal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K D","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T K","family":"Guren","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Aamdal","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K T","family":"Hagene","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Brunsvig","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Yndestad","sequence":"additional","affiliation":[{"name":"Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"K.G. Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"K.G. Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K A","family":"Tasken","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Aukrust","sequence":"additional","affiliation":[{"name":"Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway"},{"name":"K.G. Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway"},{"name":"K. G. Jebsen Thrombosis Research and Expertise Center, University of Troms\u00f8, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G M","family":"M\u00e6landsmo","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway"},{"name":"Department of Medical Biology, Faculty of Health Sciences, University of Troms\u00f8, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ueland","sequence":"additional","affiliation":[{"name":"Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"K. G. Jebsen Thrombosis Research and Expertise Center, University of Troms\u00f8, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"key":"2021121023192825400_cei13283-bib-0001","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021121023192825400_cei13283-bib-0002","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021121023192825400_cei13283-bib-0003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline \u2013 update 2016","volume":"63","author":"Garbe","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021121023192825400_cei13283-bib-0004","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a Phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021121023192825400_cei13283-bib-0005","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021121023192825400_cei13283-bib-0006","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021121023192825400_cei13283-bib-0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021121023192825400_cei13283-bib-0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021121023192825400_cei13283-bib-0009","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/annonc\/mdu441","article-title":"Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior Phase II studies","volume":"25","author":"Lebbe","year":"2014","journal-title":"Ann Oncol"},{"key":"2021121023192825400_cei13283-bib-0010","first-page":"662","article-title":"Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma","volume":"14","author":"Kahler","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"2021121023192825400_cei13283-bib-0011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","article-title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","volume":"5","author":"Gnjatic","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021121023192825400_cei13283-bib-0012","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2021121023192825400_cei13283-bib-0013","doi-asserted-by":"crossref","first-page":"75381","DOI":"10.18632\/oncotarget.18856","article-title":"Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"},{"key":"2021121023192825400_cei13283-bib-0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10555-008-9175-2","article-title":"Tumor stroma derived biomarkers in cancer","volume":"28","author":"Sund","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"2021121023192825400_cei13283-bib-0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2021121023192825400_cei13283-bib-0016","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bjc.2017.274","article-title":"Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers","volume":"117","author":"Hopkins","year":"2017","journal-title":"Br J Cancer"},{"key":"2021121023192825400_cei13283-bib-0017","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","article-title":"Predictors of responses to immune checkpoint blockade in advanced melanoma","volume":"8","author":"Jacquelot","year":"2017","journal-title":"Nat Commun"},{"key":"2021121023192825400_cei13283-bib-0018","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/cancers2010114","article-title":"Angiogenesis and melanoma","volume":"2","author":"Ribatti","year":"2010","journal-title":"Cancers (Basel)"},{"key":"2021121023192825400_cei13283-bib-0019","doi-asserted-by":"crossref","first-page":"4625472","DOI":"10.1155\/2018\/4625472","article-title":"The central role of inflammation associated with checkpoint inhibitor treatments","volume":"2018","author":"Vajaitu","year":"2018","journal-title":"J Immunol Res"},{"key":"2021121023192825400_cei13283-bib-0020","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021121023192825400_cei13283-bib-0021","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann Oncol"},{"key":"2021121023192825400_cei13283-bib-0022","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-16-0249","article-title":"Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021121023192825400_cei13283-bib-0023","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00262-014-1545-8","article-title":"Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma","volume":"63","author":"Simeone","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2021121023192825400_cei13283-bib-0024","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2021121023192825400_cei13283-bib-0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/fon.09.136","article-title":"Role of systemic inflammatory response in predicting survival in patients with primary operable cancer","volume":"6","author":"Roxburgh","year":"2010","journal-title":"Future Oncol"},{"key":"2021121023192825400_cei13283-bib-0026","doi-asserted-by":"crossref","first-page":"e1100788","DOI":"10.1080\/2162402X.2015.1100788","article-title":"Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab","volume":"5","author":"Bjoern","year":"2016","journal-title":"Oncoimmunology"},{"key":"2021121023192825400_cei13283-bib-0027","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021121023192825400_cei13283-bib-0028","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/cam4.878","article-title":"The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma","volume":"5","author":"Khoja","year":"2016","journal-title":"Cancer Med"},{"key":"2021121023192825400_cei13283-bib-0029","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.cdd.4402237","article-title":"Tumour-released exosomes and their implications in cancer immunity","volume":"15","author":"Iero","year":"2008","journal-title":"Cell Death Differ"},{"key":"2021121023192825400_cei13283-bib-0030","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ijc.26481","article-title":"Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696)","volume":"131","author":"Schaefer","year":"2012","journal-title":"Int J Cancer"},{"key":"2021121023192825400_cei13283-bib-0031","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2021121023192825400_cei13283-bib-0032","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"key":"2021121023192825400_cei13283-bib-0033","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0014-5793(00)02249-3","article-title":"Generation and degradation of human endostatin proteins by various proteinases","volume":"486","author":"Ferreras","year":"2000","journal-title":"FEBS Lett"},{"key":"2021121023192825400_cei13283-bib-0034","first-page":"8345","article-title":"Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells","volume":"63","author":"Schuch","year":"2003","journal-title":"Cancer Res"},{"key":"2021121023192825400_cei13283-bib-0035","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1096\/fj.02-0109fje","article-title":"The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells","volume":"16","author":"Hajitou","year":"2002","journal-title":"FASEB J"},{"key":"2021121023192825400_cei13283-bib-0036","first-page":"5410","article-title":"Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase","volume":"60","author":"Kim","year":"2000","journal-title":"Cancer Res"},{"key":"2021121023192825400_cei13283-bib-0037","doi-asserted-by":"crossref","first-page":"27872","DOI":"10.1074\/jbc.M202771200","article-title":"Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR\/Flk-1","volume":"277","author":"Kim","year":"2002","journal-title":"J Biol Chem"},{"key":"2021121023192825400_cei13283-bib-0038","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1097-2765(04)00102-9","article-title":"Endostatin\u2019s antiangiogenic signaling network","volume":"13","author":"Abdollahi","year":"2004","journal-title":"Mol Cell"},{"key":"2021121023192825400_cei13283-bib-0039","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/jsre.2000.5890","article-title":"The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing","volume":"91","author":"Berger","year":"2000","journal-title":"J Surg Res"},{"key":"2021121023192825400_cei13283-bib-0040","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.26343","article-title":"Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer","volume":"130","author":"Szarvas","year":"2012","journal-title":"Int J Cancer"},{"key":"2021121023192825400_cei13283-bib-0041","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/bjc.2014.456","article-title":"Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers","volume":"111","author":"Kantola","year":"2014","journal-title":"Br J Cancer"},{"key":"2021121023192825400_cei13283-bib-0042","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1002\/ijc.23468","article-title":"Expression pattern and circulating levels of endostatin in patients with pancreas cancer","volume":"122","author":"Ohlund","year":"2008","journal-title":"Int J Cancer"},{"key":"2021121023192825400_cei13283-bib-0043","first-page":"1865","article-title":"Correlations between serum levels of vascular endothelial growth factor and endostatin with clinical pathological characteristics of patients with gastrointestinal cancers","volume":"59","author":"Li","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"2021121023192825400_cei13283-bib-0044","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1757-7861.2010.00102.x","article-title":"Expression of b-FGF and endostatin and their clinical significance in human osteosarcoma","volume":"2","author":"Xu","year":"2010","journal-title":"Orthop Surg"},{"key":"2021121023192825400_cei13283-bib-0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1023\/B:GLYC.0000014085.00706.d4","article-title":"90K (Mac-2 BP) and galectins in tumor progression and metastasis","volume":"19","author":"Grassadonia","year":"2004","journal-title":"Glycoconj J"},{"key":"2021121023192825400_cei13283-bib-0046","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/bjc.1994.29","article-title":"Prognostic value of a novel circulating serum 90K antigen in breast cancer","volume":"69","author":"Iacobelli","year":"1994","journal-title":"Br J Cancer"},{"key":"2021121023192825400_cei13283-bib-0047","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/path.1125","article-title":"Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival","volume":"197","author":"Strizzi","year":"2002","journal-title":"J Pathol"},{"key":"2021121023192825400_cei13283-bib-0048","first-page":"2535","article-title":"Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients","volume":"62","author":"Marchetti","year":"2002","journal-title":"Cancer Res"},{"key":"2021121023192825400_cei13283-bib-0049","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/172460080301800311","article-title":"Are 90K\/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results","volume":"18","author":"Iacovazzi","year":"2003","journal-title":"Int J Biol Markers"},{"key":"2021121023192825400_cei13283-bib-0050","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1182\/blood.V96.9.3282","article-title":"Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo","volume":"96","author":"Fornarini","year":"2000","journal-title":"Blood"},{"key":"2021121023192825400_cei13283-bib-0051","first-page":"1069","article-title":"Pancreatic juice 90K and serum CA 19\u20139 combined determination can discriminate between pancreatic cancer and chronic pancreatitis","volume":"90","author":"Gentiloni","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"2021121023192825400_cei13283-bib-0052","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12967-015-0606-x","article-title":"Prognostic relevance of LGALS3BP in human colorectal carcinoma","volume":"13","author":"Piccolo","year":"2015","journal-title":"J Transl Med"},{"key":"2021121023192825400_cei13283-bib-0053","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1523-1747.2002.17642.x","article-title":"Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions","volume":"119","author":"Cesinaro","year":"2002","journal-title":"J Invest Dermatol"},{"key":"2021121023192825400_cei13283-bib-0054","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.21820","article-title":"Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?","volume":"119","author":"Reynolds","year":"2006","journal-title":"Int J Cancer"},{"key":"2021121023192825400_cei13283-bib-0055","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.0022-202X.2005.23798.x","article-title":"Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma","volume":"125","author":"Vergilis","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2021121023192825400_cei13283-bib-0056","doi-asserted-by":"crossref","first-page":"e1440930","DOI":"10.1080\/2162402X.2018.1440930","article-title":"Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma","volume":"7","author":"Wu","year":"2018","journal-title":"Oncoimmunology"},{"key":"2021121023192825400_cei13283-bib-0057","doi-asserted-by":"crossref","first-page":"e1434467","DOI":"10.1080\/2162402X.2018.1434467","article-title":"The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment","volume":"7","author":"Farhad","year":"2018","journal-title":"Oncoimmunology"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13283","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/197\/1\/74\/41637705\/cei13283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/197\/1\/74\/41637705\/cei13283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:26:15Z","timestamp":1641054375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/197\/1\/74\/6402542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,3,21]]},"published-print":{"date-parts":[[2019,6,24]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13283","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,3,21]]}}}